TLR5 and neoplasm: Consistent with previous results (Fig. 2b), Tlr5+/+ mice treated with CBLB502 (low dose) + ICT treatments resulted in 20% tumor-free mice (n = 10) (Fig. 2d and Supplementary Fig. 6d, mice 2 and 4).